



GMM/SEC/2025-26/08

May 21, 2025

To,
BSE Limited
Scrip Code: 505255

National Stock Exchange of India Limited
Symbol: GMMPFADLR

Sub.: Press Release on the Audited Standalone and Consolidated Financial Results of GMM Pfaudler Limited ("the Company") for the year ended March 31, 2025

Dear Sir/ Ma'am,

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release on the Audited Standalone and Consolidated Financial Results of the Company for the year ended March 31, 2025.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For **GMM Pfaudler Limited**

Mittal Mehta
Company Secretary & Compliance Officer
FCS. No. 7848

Encl.: As above

GMM Pfaudler Ltd.

Corporate Office: 902 VIOS Tower, New Cuffe Parade, Sewri-Chembur Rd, Mumbai 400037
Registered Office & Works: Vithal Udyognagar, Anand - Sojitra Road, Karamsad - 388325
O: +91 22 6650 3900 | F: +91 2692 661888 | CIN: L29199GJ1962PLC001171
W: www.gmmpfaudler.com | E: sales@gmmpfaudler.com



Quarterly & Annual Earnings Release | Q4/12M FY25

Mumbai, May 21, 2025: GMM Pfaudler Limited, global leader in corrosion-resistant technologies, systems, and services, announces its fourth quarter (Q4 FY25) and annual (FY25) results for the period ended March 31, 2025.

Financial Performance

Consolidated

| Q4 FY25 | Revenue | EBITDA* | EBITDA Margin* | PAT* | PAT Margin* | EPS* | Order Intake | Order Backlog |
|------------|------------|-----------|-------------------|-----------|----------------|-------|-----------------|------------------|
| | ₹807 Crore | ₹93 Crore | 11.5% | ₹15 Crore | 1.9% | ₹3.58 | ₹660 Crore | ₹1,636 Crore |

| FY25 | Revenue | EBITDA* | EBITDA Margin* | PAT* | PAT Margin* | EPS* | Order Intake | Order Backlog |
|------|--------------|------------|-------------------|------------|----------------|--------|-----------------|------------------|
| | ₹3,199 Crore | ₹381 Crore | 11.9% | ₹100 Crore | 3.1% | ₹22.99 | ₹3,102 Crore | ₹1,636 Crore |

* Notes:

i. EBITDA is before considering one-time costs for the India EBITDA transformation program in Q4 FY25 & FY25 and Hyderabad, India site closure costs in FY25, totaling to ₹ 9.8 crore for Q4 FY25 and ₹ 19.6 crore for FY25.

ii. PAT is before one-time costs as explained in note i. above and before one-time exceptional costs pertaining to Leven, UK site closure, consisting of severance pay, inventory write-offs, asset impairment and other closure costs amounting to ₹ 47.7 crore for Q4 FY25 & FY25 (Total net of tax ₹ 43 crore for Q4 FY25 & ₹ 50.4 crore for FY25).

iii. EPS is calculated considering the adjusted PAT as explained in note ii. above for Q4 FY25 & FY25.

Key Highlights

Consolidated:

- FY25 Revenue and EBITDA* down by 7% and 20% respectively compared to the previous year
- Q4 Revenue and EBITDA* up 9% and 4% respectively compared to the same period previous year
- Order Intake at ₹3,102 crore, up 3% compared to the previous year
- Order Backlog stands at ₹1,636 crore, down 3% compared to the previous year
- Global Manufacturing Footprint optimization continues:
 - Closure of Leven, UK site will be completed by Q2 FY26
 - Closure of Hyderabad, India site completed
 - Low-cost manufacturing site in Poland established; capacity increase program initiated
- Strong free cash flow generation of ₹ 318 crore in FY25, an improvement of ₹ 97 crore over previous year

India:

- Strong performance in Q4 with Revenue of ₹ 252 crore and EBITDA* of ₹44 crore, EBITDA* Margin at 17.4%
- Significant Improvement in profitability in H2 FY25 due to an increase in volume, favorable product mix, and an ongoing cost optimization program, the benefits of which will continue into FY26
- Opening Order Backlog for FY26 is higher by 20% at ₹549 crore



Quarterly & Annual Earnings Release | Q4/12M FY25

Other Business Highlights:

- Mr. Gregory Gelhaus appointed as Chief Transformation Officer
- The Board recommended a final dividend of ₹1 per equity share, subject to requisite approvals. Total dividend for FY25 (including interim dividend) would be ₹2 per equity share

Management Comment

Commenting on the Company's Q4 & FY25 results, **Mr. Tarak Patel, Managing Director** said, "This year has been challenging, primarily due to a general slowdown in the chemical and pharmaceutical sectors. Additionally, uncertainties surrounding global trade and geopolitical tensions have further complicated the situation. However, our focus on diversification and cost optimisation has enabled us to navigate these difficulties effectively. Our performance, particularly in India during the second half of the year, reflects this success and sets a positive trajectory for the new financial year. Nonetheless, our international business continues to face challenges related to the uncertain US tariff situation, which remains unresolved at this time. Our global manufacturing footprint optimization program is ongoing, with the establishment of our new low-cost manufacturing site in Poland and the closure of our manufacturing sites in Leven, UK, and Hyderabad, India."

He further added, "We are delighted to welcome Greg as Chief Transformation Officer. I am confident his extensive experience across various industries and geographies will be a tremendous asset to the company and the management team."



Quarterly & Annual Earnings Release | Q4/12M FY25

Audited results for the quarter and year ended March 31, 2025, prepared under Ind AS, is available in the Investor Relations section of our website www.gmmpfaudler.com

Quarterly Conference Call

The company will hold an earnings conference call on Wednesday, May 21, 2025, at 6:00 PM (Indian Standard Time) to discuss the unaudited financial results and performance of the Company for the quarter and year ended March 31, 2025.

The audio conference call will be accessible from all networks and countries through universal access dial-ins:

+91 22 6280 1341 / +91 22 7115 8242 or at [weblink](#)

The Q4 & FY25 Earnings presentation will be submitted to Stock Exchanges and shall also be hosted on the Company's website at www.gmmpfaudler.com

About GMM Pfaudler Limited

GMM Pfaudler Limited delivers corrosion-resistant technologies, systems, and services worldwide, and it remains the preferred choice by consistently providing its customers in the chemical, pharmaceutical, and other process industries with innovative and cost-effective solutions. GMM Pfaudler Limited has 19 manufacturing locations, an extensive sales and service network, and employs more than 2000 people across 4 continents.

More information is available at www.gmmpfaudler.com

Contact details

| Company | Investor | Media |
|---|---|---|
| Dhaval Rajput GM Finance & Accounts, GMM Pfaudler Ltd. Tel: +91 22 6650 3900 Email: investorrelations@gmmpfaudler.com | Anuj Sonpal Valorem Advisors Tel: +91 22 4903 9500 Email: gmmpfaudler@valoremadvisors.com | Abhishek Savant Veritas Reputation PR Private Ltd. Tel: +91 8108848822 Email: abhishek@veritasreputation.com |

Disclaimer:

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. GMM Pfaudler Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances